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1. Introduction 
During the last years, increasing attention has been 
focused on the non-coordinate expression of murine 
leukemia virus envelope giycoproteins in the organs 
and serum from different inbred strains of mice 
[1-4]. Most of these proteins have been detected by 
using broadly reactive interspecies competition radio- 
immunoassays. The purification of the endogenous 
AKR-type virus gp71 [5] was used to develop an 
homologous type-specific assay against hat protein. 
By using such an assay, an AKR gp7 l-like antigen 
has been detected in the bone marrow of all strains of 
inbred as well as wild mice tested [4]. These strains 
include high, low and non-virus trains in addition to 
NIH Swiss, a strain lacking a portion (<50%) of the 
viral genome [6]. That AKR-like gp71 is so highly 
conserved evolutionary in bone marrow cells and that 
this antigen can not be demonstrated in peripheral 
lymphoid organs, could indicate that this protein 
plays some role in a primitive stage of lymphoid 
development and differentiation. Lymphoid cell dif- 
ferentiation is currently one of the best understood. 
The aim of this work is to purify the AKR-like gp71 
antigen from mouse bone marrow, to further estab- 
lish its nature and compare it structurally with some 
viral proteins. 
2. Materials and methods 
AKR gp71, Rauscher gp71, Moloney gp71 and 
Balb/c (X) gp71 were purified as in [5]. Goat anti- 
Tween-ether-disrupted AKR MuLV and Moloney- 
MuLV antisera was obtained through the Resources 
and Logistics Program of the National Cancer Insti- 
tute. Antiserum against AKR gp71 was prepared as in 
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[5]. Viral and bone marrow proteins were labeled 
with Na12SI according to [7]. 
Bone marrow cells from femurs and tibiae of 
Balb/c and NIH Swiss mice were homogenized in 1% 
Triton X-100, 1 M KC1,0.1 M sodium phosphate buffer 
(pH 7) containing 1#g/ml phenylmethylsulfonyl 
fluoride (PMSF). After centrifugation, the post- 
microsomal cell extracts were stored in liquid nitrogen. 
Protein concentrations were determined as in [8]. 
2.1. Purification 
Homogenate (1 ml) from 25 bone marrows (45 mg 
protein) was applied to a 2 × 35 cm column of 
Sepharose 4B which was eluted at 4°C with TNE 
(0.01 M Tris-HC1, 0.1 M NaC1, 0.001 M EDTA 
(pH 7.5)) containing 1/ag PMSF/ml. Fractions (2 ml) 
were collected and monitored for absorbance at
280 nm. Each fraction was tested for competition i
the homologous anti-AKR gp71-AKR gp71 cRIA. 
Fractions containing competing activity were pooled, 
dialyzed overnight against 0.01 M Tris-HC1, 0.001 M 
EDTA (pH 7.8) and applied to a Whatman DE-32 
column pre-equilibrated with the same buffer. After 
washing, bound proteins were eluted with a linear 
gradient of KC1 (0-0.5 M). Individual fractions were 
tested for protein and, after dialysis against TNE, 
assayed for AKR gp71 reactivity in cRIA. 
For immunoaffinity chromatography 0.4 mg pure 
Moloney gp71 were coupled to 1 ml activated 
Sepharose 4B following the standard Pharmacia pro- 
cedure. A high titer goat anti-Tween-ether-disrupted 
Moloney leukemia virus was used as a source of anti- 
group-specific antibodies. Heat-inactivated (56°C, 
30 min) antiserum (1 ml) diluted 1:5 in PBS, was 
passed over the Moloney gp71 column at 5 ml/h. The 
column was washed with PBS until free of absorbance 
at 280 nm and the bound antibody eluted with 3 M 
KSCN. After dialysis against PBS the antibody prepa- 
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ration (3.6 mg) was concentrated by Diaflo P-30 
ultrafiltration and checked for precipitating activity 
against 12SI-Moloney gp71. That antibody preparation 
was coupled as above to 1 ml activated Sepharose 4B 
and used for bone marrow gp71 immunoaffinity puri- 
fication. The peak activity fractions of the DEAE- 
cellulose column were passed on the above column, 
which was pre-washed with TNE. After washing, the 
column was eluted with a gradient of trichloroacetic 
acid (0-2 M) pH 6.9 at 4°C. Following exhaustive 
dialysis against TNE, the eluted gp71 was concen- 
trated by vacuum dialysis and labelled with 125I. 
This material was further purified by immunopre- 
cipitation, essentially as in [9]. The labelled antigen 
was incubated with the appropriate amount of anti- 
AKR-MuLV antiserum or normal control serum and 
incubated for 1 h at 37°C and 4°C overnight. Then 
100/~l of a 10% suspension of killed Staphylococcus 
aureus Cowan strain pre-washed with TNE + 0.1% 
Triton X-100 was added and the mixture incubated 
for 15 min at room temperature. The antigen-anti- 
body-Staphylococcus complex was processed as in 
[10]. Briefly, after 3 washes with TNET, the com- 
plex was boiled in 2% sodium dodecyl sulfate (SDS), 
2%/3-mercaptoethanol, 0.01M sodium phosphate 
(pH 7) for 1 min, centrifuged and the supernatant 
subjected to SDS-polyacrylamide g lelectrophoresis 
asin [11]. 
2.2. Peptide mapping 
The peptide mapping was performed as follows: 
1 mm slices from polyacrylamide g l electrophoresis 
containing the pure gp71 were pooled, washed over- 
night in 50% methanol, 10% acetic acid and digested 
overnight with 50 #g TPCK-trypsin (Worthington) in
0.1 M ammonium bicarbonate (pH 8). The buffer 
containing the peptides was lyophilized, rehydrated 
in the chromatographic eluent and spotted on cellu- 
lose thin-layer chromatography plates for two-dimen- 
sional peptide mapping according to the procedures 
in [12,131. 
2.3. Lectin affinity chromatography 
For lectin column affinity chromatography, 20 mg 
lectin from Lens culinaris (Boehringer Mannheim 
Biochemicals) were bound to 2 g activated Sepharose 
4B in the presence of 0.1 M c~-methyl-glucopyrano- 
side. Concanavalin A-Sepharose was purchased from 
Pharmacia Fine Chemicals. Labelled samples in phos- 
phate buffered saline (PBS) containing BSA (0.5 rag/ 
nrl) were added to 0.5 X 3 cm, siliconized columns at 
room temperature and then washed with the same 
buffer until cpm reached background levels. Bound 
protein was eluted by washing the columns with 
0.2 M a-methyl-mannopyranoside. 
3. Resu l ts  
3.1. Bone marrow AKR-MuL V gp 71-like purification 
The Sepharose 4B column was used to remove 
nucleic acid and a part of the concomitant proteins. 
The results of a typical chromatography of a bone 
marrow homogenate sample is shown in fig.1. A first 
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Fig.1. Sepharose 4B elution profile of murine bone marrow homogenate. The chromatography conditions were as in section 2. 
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Fig.2. DEAE-cellulose chromatography of the active fractions 2o 
from fig.1. After dialysis, the fractions were pooled and [~ \ 
chromatographed on aDEAE-cellulose column as in section 2. 16 
KClsurements.COncentrations were determined by conductivity mea- li1 i ~" ]'%/'" ° ~/ i  n!! i~i"\  
peak of nucleic acid is excluded from the column, fol- \ 
lowed by a flat plateau of medium weight material ~ . . . .  x ...~ ~;  .,,~..,._ . . .  
and another two-shouldered peak. The bone marrow ~, .  -,¢'~ 
material that competes in the AKR gp71 homologous 
cRIA elutes as a broad peak in the first half of the 
last protein peak. The elution position of that mate- 
rial is roughly the same as that occupied by a sample 
of 12SI-Rauscher gp71. The broad shape of the tissue 
AKR gp7 l-like protein peak can be explained by 
some degradation of the material or by the experi- 
mental fact that glycoproteins are non-specifically 
retained in agarose columns. Fractions with the high- 
est level of reactivity were pooled, dialyzed and 
applied to a DEAE-ceUulose column. The elution pro- 
file obtained is illustrated in fig.2. One peak of com- 
peting activity is eluted from the column at 0.i M 
Table 1 
Purification of AKR gp71 from mouse bone marrow 
Purification step Total Purification Yield 
protein (mg) (-fold) (%) 
Crude homogenate 115 1 100 
Sepharose 4B 28 4 95 
DEAE-cellulose 6.3 18 36 
Immunoaffinity 0.003 38.3 13 
Mouse bone marrow gp71 was purified by a 3-step urifica- 
tion procedure according to section 2.2. Final yield was 13% 
with 38.3-times purification 
10 20 30 40 10 20 30 40 
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Fig.3. SDS-polyacrylamide gel electrophoresis of 12s I-labelled 
gp71 preparations purified by immunoprecipitation. Bars 
represent slices of the gels pooled for peptide mapping: (A) 
Balb/c bone marrow gp71 ;(B) AKR MuLV gp71 ;(C) NIH 
Swiss bone marrow gp71; (D) Balb (X) gp71. 
KC1. This peak elutes lightly ahead of the major pro- 
tein peak. Nevertheless, a considerable purification 
and concentration f the AKR gp71-1ike activity is 
obtained by using such a column. The 2 preceding 
steps were necessary to accomplish a satisfactory 
purification with the antibody affinity column. A 
high titer goat anti-Moloney MuLV antiserum was 
chosen as a source of group-specific antibodies against 
the AKR gp71-1ike bone marrow antigen, to prepare 
the immunoaffinity column. Previous competition 
RIA demonstrate hat the bone marrow extracts com- 
pete in the group specific assay. The elution of the 
tissue antigen for such a column was ~30% efficient 
and the final yield of ~13% (table 1). The material 
eluted from the column was labelled with 12sI and 
immunoprecipitated with increasing 2-fold dilutions 
of rabbit anti-AKR gp71 or goat anti-AKR-MuLV. A 
binding plateau of 25% maximum precipitation was 
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reached with both antisera (not shown) indicating 
that only this percent of material is still able to bind 
antibody. 
3.2. Peptide mapping 
Both viral and bone marrow gp71 were further 
purified by immunoprecipitation. Of the counts used, 
~28% were consistently recovered bound to the 
Staphylococci omplex. After boiling, the super- 
natants were run on SDS-polyacrylamide g ls. The 
profiles obtained were as illustrated in fig.3. 
A discrete peak moving to the same zone in which 
viral gp71 is found. Nevertheless, a significant break- 
down can be observed. The fragments eem to retain 
their immunological capacity since they are still able to 
bind antibody. Fig.4 shows the tryptic peptide maps 
of bone marrow, AKR-MuLV and Balb (X) gp71. A 
clear distinct pattern of spot distribution is observed 
in each case. Tile comparison of the bone marrow 
antigens with both viral products hows that the tis- 
sue gp71 resembles more the xenotropic than the 
AKR map. The NIH bone marrow protein looks 
like the xenotropic virus gpT1 too. Thus, the anti- 
genic relation is not accompanied by a clear struc- 
tural similarity. 
3.3. Glycosylated nature of the bone marrow antigens 
Concanavalin A and Lens culinaris lectin have 
affinity for glucose and mannose containing lyco- 
proteins. We tested that ability of both lectins cova- 
lently linked to Sepharose 4B to bind the immuno- 
affinity-purified bone marrow antigens as well as 
AKR MuLV gp71. The results of those affinity chro- 
matography experiments are summarized in table 2. 
Both NIH Swiss and Balb/c bone marrow prepara- 
tions bind in a significant extent to the immobilized 
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Fig.4. Comparison of the tyrosine-containing tryptic peptides of: (A) AKR MuLV gp71 ; (B) Balb (X) MuLV gp71 ; (C) Balb/c 
bone marrow; (D) NIH Swiss bone marrow gpT1. 
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Table 2 
Lectin affinity chromatography of bone marrow and AKR MuLV gp71 
Chromatographed sample Con A Lentil lectin Sepharose 4B 
column (%) column (%) column (%) 
NIH bone marrow antigen 66 31 15 
Balb/c bone marrow antigen 47 39 18 
AKR MuLV gp71 92 80 21 
Percent of binding to immobilized lectins and Sepharose matrix from 3 t~SI4abelled samples 
lectins. Concanavalin A seems to have higher affinity 
than the lentil tectin for both antigens, but when we 
eluted the bound protein with methyl mannoside, 
only 22% is recovered. Elution from the lentil lectin 
column is almost wice as efficient (43%). Despite the 
addition of BSA to the chromatography buffer, 
~15% of the input cpm binds non-specifically to a 
Sepharose 4B column. The results of the chromatog- 
raphy of a sample of AKR gp71 is shown for com- 
parison. 92% and 80% of the input cpm bind to the 
lectins and some 21% non-specific binding is found. 
This particular preparation of gp71 was 95% precipit- 
able by the antiserum. Keeping in mind that our 
bone marrow preparations are only 25% precipitable, 
we conclude that this material is glycosylated in 
nature. The elution behavior from the Sepharose col- 
umn (fig.i) and the migration in the SDS-polyacryl- 
amide gels in the same position as the viral gp71 
control (fig.3), allow us to conclude that the bone 
marrow antigen is also a glycoprotein of 70 000-  
71 O00M r. 
4. Discussion 
The AKR gp714ike antigen accounts for 180 and 
140 ng/mg total bone marrow protein in Balb/c and 
NIH Swiss mice, respectively. The mean values for 
seric gp71 in 2-month-old animals of the same strains 
are 260 and 240 ng/mg [4]; those antigens are highly 
tissue-specific, the xenotropic gp71 being detected 
only in serum [4]. The bone marrow is the main 
source of precursors of lymphoid as well as hemo- 
poietic cells. The fact that no AKR4ike antigen can 
be detected in peripheral lymphoid organs could indi- 
cate that it is a host product playing some role in 
the early stages of lymphoid or erythroid cell differ- 
entiation. A direct comparison of the primary struc- 
ture of the bone marrow product with viral envelope 
proteins can help to answer the question if this anti- 
gen is more 'virus-like' than 'host-like'. 
Here, we report he comparison of the tyrosine- 
containing peptide maps of the purified bone marrow 
product with those of the gp71 of 2 viruses known to 
be harbored by NIH Swiss and Balb/c mice. In fact, 
the Balb/c strain contains genetic information coding 
for at least 3 distinguishable type-C oncornavirus 
[14]. NIH Swiss contains information for type II and 
III xenotropic virus production [3] and partial 
information for type I virus [6]. The patterns of spot 
distribution in the bone marrow gp71 peptide maps 
seem to indicate some similarity with the Balb (X) 
gp71 rather than with the AKR glycoprotein. Both 
tissue products eem to be distinct from the purified 
viral proteins, suggesting they are more 'host-like' 
complex products bearing some antigenic determi- 
nants from the envelope viral product of endogenous 
type I MuLV. This complex cellular product could be 
the result of a recombinant event. 
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